Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.56 |
| ▸ | PPARD | Q03181 | 4/20 | 0.56 |
| ▸ | PPARA | Q07869 | 4/20 | 0.56 |
| ▸ | TERT | O14746 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | F7 | P08709 | 2/20 | 0.56 |
| ▸ | F3 | P13726 | 2/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541950 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL10629296 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL28938360 | 1.00 | LMNA (0.63) | LMNATSHRNFKB1PMP22MAPT | |
| SCHEMBL10406103 | 0.97 | — | — | |
| SCHEMBL4955090 | 0.93 | PPARG (0.67) | LMNATSHRMAPTPPARGPPARD | |
| SCHEMBL10406413 | 0.89 | — | — | |
| SCHEMBL25293847 | 0.81 | PPARG (0.78) | LMNATSHRMAPTPPARGPPARD | |
| SCHEMBL864021 | 0.81 | PPARG (0.78) | LMNATSHRMAPTPPARGPPARD | |
| SCHEMBL3898132 | 0.81 | PPARG (0.78) | LMNATSHRMAPTPPARGPPARD | |
| SCHEMBL2937780 | 0.81 | PPARG (0.78) | LMNATSHRMAPTPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311184-A1 | METHOD FOR DEVELOPING, TESTING, AND USING ASSOCIATES OF MACROMOLECULES AND COMPLEX AGGREGATES FOR IMPROVED PAYLOAD AND CONTROLLABLE DE/ASSOCIATION RATES | IDEA AG (DE) | 2008-12-18 | — | — | US | claimed |
| US-20240099976-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2024-03-28 | — | — | US | disclosed |
| US-11547665-B2 | Multiphasic compositions | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2023-01-10 | — | — | US | disclosed |
| CN-115461360-A | Sustained GLP-1 and glucagon receptor dual agonists | 东亚ST株式会社 | 2022-12-09 | — | — | CN | disclosed |
| EP-3954361-A1 | MULTIPHASIC COMPOSITIONS | Sequessome Technology Holdings Limited (MT) | 2022-02-16 | — | — | EP | disclosed |
| US-20220031615-A1 | VESICLES | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2022-02-03 | — | — | US | disclosed |
| US-20210393655-A1 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-12-23 | — | — | US | disclosed |
| EP-3316857-B1 | MULTIPHASIC COMPOSITIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-08-04 | — | — | EP | disclosed |
| EP-3316856-B1 | BLENDED FORMULATIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-04-07 | — | — | EP | disclosed |
| US-20210023007-A1 | BLENDED FORMULATIONS | SEQUESSOME TECH HOLDINGS LIMITED (US) | 2021-01-28 | — | — | US | disclosed |
| EP-1551370-B1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CEVC GREGOR | 2007-02-08 | — | — | US | disclosed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | disclosed |
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | IDEA AG (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | SLC43A1, TRPV2, TRPA1 | LMNA 1492/4885TSHR 4716/4885NFKB1 165/4885 |
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | LMNA 891/4885TSHR 3410/4885NFKB1 3233/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | LMNA 891/4885TSHR 3410/4885NFKB1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.